High expression levels of class III β-tubulin in resected non-small cell lung cancer patients are predictive of improved patient survival after vinorelbine-based adjuvant chemotherapy

Oncology Letters

Volumn 6, Issue 1, 2013, Pages 220-226

  Zhang, Yalei ^a,b   Yang, Haihong ^a,b   Liu, Jun ^b   Deng, Qiuhua ^b   He, Ping ^b   Lin, Yunen ^b   Jiang, Juhong ^b   Gu, Xia ^b   Mo, Mingcong ^b   Pan, Hui ^b   Xiong, Xinguo ^b   Qiu, Yuan ^b   He, Jianxing ^b  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Adjuvant chemotherapy; Class III tubulin; Resected non small cell lung cancer

Indexed keywords

BETA TUBULIN; CARBOPLATIN; CISPLATIN; NAVELBINE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PREDICTIVE VALUE; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SURVIVAL PREDICTION; TREATMENT OUTCOME;

EID: 84878285846     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1323     Document Type: Article

References (18)

1. Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Sève P, Lai R, Ding K, et al: Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10. Clin Cancer Res 13: 994-999, 2007.
3. Kato H, Ichinose Y, Ohta M, et al: A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 350: 1713-1721, 2004.
4. Arriagada R, Bergman B, Dunant A, et al; International Adjuvant Lung Cancer Trial Collaborative Group: Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350: 351-360, 2004.
5. Hotta K, Matsuo K, Ueoka H, et al: Role of adjuvant chemotherapy in patients with resected non-small-cell lung cancer: reappraisal with a meta-analysis of randomized controlled trials. J Clin Oncol 22: 3860-3867, 2004.
6. Dumontet C and Sikic BI: Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol 17: 1061-1070, 1999.
7. Sullivan KF: Structure and utilization of tubulin isotypes. Annu Rev Cell Biol 4: 687-716, 1988.
8. Dumontet C, Durán GE, Steger KA, Murphy GL, Sussman HH and Sikic BI: Differential expression of tubulin isotypes during the cell cycle. Cell Motil Cytoskeleton 35: 49-58, 1996.
9. Verdier-Pinard P, Wang F, Martello L, Burd B, Orr GA and Horwitz SB: Analysis of tubulin isotypes and mutations from taxol-resistant cells by combined isoelectrofocusing and mass spectrometry. Biochemistry 42: 5349-5357, 2003.
10. Nicoletti MI, Valoti G, Giannakakou P, et al: Expression of beta-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-Anticancer Drug Screen: correlation with sensitivity to microtubule active agents. Clin Cancer Res 7: 2912-2922, 2001.
11. Kavallaris M, Kuo DY, Burkhart CA, et al: Taxol resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest 100: 1282-1293, 1997.
12. Ludueña RF: Are tubulin isotypes functionally significant. Mol Biol Cell 4: 445-457, 1993.
13. Mountain CF: Revisions in the International System for Staging Lung Cancer. Chest 111: 1710-1717, 1997.
14. Sève P, Isaac S, Trédan O, et al: Expression of class III (beta)-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res 11: 5481-5486, 2005.
15. Aschele C, Debernardis D, Casazza S, et al: Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. J Clin Oncol 17: 1760-1770, 1999.
16. Edler D, Glimelius B, Hallström M, et al: Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J Clin Oncol 20: 1721-1728, 2002.
17. Sarries C, Haura EB, Roig B, et al: Pharmacogenomic strategies for developing customized chemotherapy in non-small cell lung cancer. Pharmacogenomics 3: 763-780, 2002.
18. Hirai Y, Yoshimasu T, Oura S, et al: Is class III beta-tubulin a true predictive marker of sensitivity to vinorelbine in non-small cell lung cancer? Chemosensitivity data evidence. Anticancer Res 31: 999-1005, 2011.